Cargando…

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models()

BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibitor crizotinib has proven to be effective in the treatment of ALK-mutated neuroblastoma, but crizotinib resistance was commonly observed in patients. We aimed to overcome crizotinib resistance by combining with the MEK inhibitor trametinib or low-do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Libo, Wu, Bing, Baruchel, Sylvain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2017
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491461/ https://www.ncbi.nlm.nih.gov/pubmed/28666189 http://dx.doi.org/10.1016/j.tranon.2017.04.008

Ejemplares similares

Multifocal Neuroblastoma and Central Hypoventilation in An Infant with Germline ALK F1174I Mutation
por: Djos, Anna, et al.
Publicado: (2022)

ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT
por: Debruyne, D N, et al.
Publicado: (2016)

Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma
por: Liu, Tingting, et al.
Publicado: (2021)

A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance
por: Wang, Ye, et al.
Publicado: (2019)

The mutational landscape of MYCN, Lin28b and ALK(F1174L) driven murine neuroblastoma mimics human disease
por: De Wilde, Bram, et al.
Publicado: (2017)

Intrinsic Susceptibility MRI Identifies Tumors with ALK(F1174L) Mutation in Genetically-Engineered Murine Models of High-Risk Neuroblastoma
por: Jamin, Yann, et al.
Publicado: (2014)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
por: Taschner-Mandl, Sabine, et al.
Publicado: (2015)

Oncogenic ALK(F1174L) drives tumorigenesis in cutaneous squamous cell carcinoma
por: Gualandi, Marco, et al.
Publicado: (2020)

Expression of the Neuroblastoma-Associated ALK-F1174L Activating Mutation During Embryogenesis Impairs the Differentiation of Neural Crest Progenitors in Sympathetic Ganglia
por: Vivancos Stalin, Lucie, et al.
Publicado: (2019)

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
por: Hackl, Christina, et al.
Publicado: (2013)

Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L
por: Najem, Safiullah, et al.
Publicado: (2016)

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial
por: Manji, Arif, et al.
Publicado: (2022)

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
por: Di Desidero, Teresa, et al.
Publicado: (2015)

Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer
por: Yan, Hong Hua, et al.
Publicado: (2014)

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells
por: Montavon, Gisèle, et al.
Publicado: (2014)

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis
por: Wang, Yongfeng, et al.
Publicado: (2016)

An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids
por: Jyoti, Amar, et al.
Publicado: (2015)

Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity
por: Chuang, Yu-Chung, et al.
Publicado: (2019)

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
por: Tucker, Elizabeth R., et al.
Publicado: (2023)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer
por: Mitra Ghosh, Taraswi, et al.
Publicado: (2021)

Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
por: Mitra Ghosh, Taraswi, et al.
Publicado: (2023)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
por: Moore, Nathan F., et al.
Publicado: (2014)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
por: Shi, Wenyu
Publicado: (2023)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report
por: Zhao, Jiuzhou, et al.
Publicado: (2022)

L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites
por: Li, Jian, et al.
Publicado: (2017)

An Orthopedic Clinic of 1174 A.D.
por: Cravener, Edward K.
Publicado: (1931)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

The Lipophilic Purine Nucleoside—Tdp1 Inhibitor—Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo
por: Chernyshova, Irina A., et al.
Publicado: (2022)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Boulos, Joelle C., et al.
Publicado: (2021)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
por: Zhang, Xiangming, et al.
Publicado: (2023)

Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan
por: Chaturvedi, Nagendra K., et al.
Publicado: (2016)

Complete response with crizotinib in two children with chemotherapy resistant neuroblastoma
por: Verma, Priyanka, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pl9lc15ns4nukoo4ulttu0povi